相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effect of treatment with iloprost with or without bosentan on nailfold videocapillaroscopic alterations in patients with systemic sclerosis
Valentina Cestelli et al.
MODERN RHEUMATOLOGY (2017)
The myth of loss of angiogenesis in systemic sclerosis: a pivotal early pathogenetic process or just a late unavoidable event?
Marco Matucci-Cerinic et al.
ARTHRITIS RESEARCH & THERAPY (2017)
Digital ulcers in scleroderma patients: A retrospective observational study
A. De Cata et al.
INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY (2016)
Efficacy of Raynaud's phenomenon and digital ulcer pharmacological treatment in systemic sclerosis patients: a systematic literature review
Paloma Garcia de la Pena Lefebvre et al.
RHEUMATOLOGY INTERNATIONAL (2015)
Evidence for oesophageal and anorectal involvement in very early systemic sclerosis (VEDOSS): report from a single VEDOSS/EUSTAR centre
Gemma Lepri et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Longterm Treatment with Endothelin Receptor Antagonist Bosentan and Iloprost Improves Fingertip Blood Perfusion in Systemic Sclerosis
Maurizio Cutolo et al.
JOURNAL OF RHEUMATOLOGY (2014)
Review: Evidence That Systemic Sclerosis Is a Vascular Disease
Marco Matucci-Cerinic et al.
ARTHRITIS AND RHEUMATISM (2013)
2013 Classification Criteria for Systemic Sclerosis An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
Frank van den Hoogen et al.
ARTHRITIS AND RHEUMATISM (2013)
Vascular Leak Is a Central Feature in the Pathogenesis of Systemic Sclerosis
Tracy M. Frech et al.
JOURNAL OF RHEUMATOLOGY (2012)
Angiogenesis and Vasculopathy in Systemic Sclerosis: Evolving Concepts
Bradley J. Rabquer et al.
CURRENT RHEUMATOLOGY REPORTS (2012)
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial
Marco Matucci-Cerinic et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Modified-Release Sildenafil Reduces Raynaud's Phenomenon Attack Frequency in Limited Cutaneous Systemic Sclerosis
Ariane L. Herrick et al.
ARTHRITIS AND RHEUMATISM (2011)
Oral sildenafil in skin ulcers secondary to systemic sclerosis
A. Della Rossa et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2011)
Iloprost modulates the immune response in systemic sclerosis
Patrizia D'Amelio et al.
BMC IMMUNOLOGY (2010)
EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)
O. Kowal-Bielecka et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
A score of risk factors associated with ischemic digital ulcers in patients affected by systemic sclerosis treated with iloprost
Paola Caramaschi et al.
CLINICAL RHEUMATOLOGY (2009)
Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis
M. E. Hettema et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol
G. Milio et al.
RHEUMATOLOGY (2006)
Efficacy and tolerability of a selective α2C-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients -: A single-center, double-blind, placebo-controlled, randomized crossover study
RA Wise et al.
ARTHRITIS AND RHEUMATISM (2004)
Prostacyclin inhibits adhesion of polymor-phonuclear leukocytes to human vascular endothelial cells due to adhesion molecule independent regulatory mechanisms
S Lindemann et al.
BASIC RESEARCH IN CARDIOLOGY (2003)
Prostacyclin derivatives prevent the fibrotic response to TGFβ2 by inhibiting the Ras/MEK/ERK pathway
R Stratton et al.
FASEB JOURNAL (2002)
Systemic sclerosis therapy with iloprost:: A prospective observational study of 30 patients treated for a median of 3 years
L Bettoni et al.
CLINICAL RHEUMATOLOGY (2002)
Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients
R Stratton et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
分享论文
